Immuneering Corp (IMRX) stock
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Earnings
Immuneering's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Immuneering's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 5, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026after the close | – | – | -$0.37 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 6, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025during market hours | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025during market hours | – | – | -$0.40 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025during market hours | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024during market hours | – | – | -$0.49 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | – | – | -$0.47 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | – | – | -$0.49 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 1, 2024before the open | – | – | -$0.52 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | – | – | -$0.43 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | – | – | -$0.43 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 18, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023during market hours | – | – | -$0.50 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$0.49 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | – | – | -$0.44 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022before the open | – | – | -$0.49 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022before the open | – | – | -$0.42 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Sep 9, 2021before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Immuneering guided for has been reported
Guidance history
Every forecast Immuneering put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2022 | GAAP operating expenses | FY2022 | $53.00M – $56.00M | Lowered |
| Aug 10, 2022 | GAAP operating expenses | FY2022 | $55.00M – $60.00M | Reaffirmed |
| May 10, 2022 | GAAP operating expenses | FY2022 | $55.00M – $60.00M | Reaffirmed |
| Mar 10, 2022 | GAAP operating expenses | FY2022 | $55.00M – $60.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Immuneering filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?